LLY vs DXCM
By Alex · Tickerpine
Eli Lilly and Company vs DexCom, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | DXCM |
|---|---|---|
| Price | $1,220.28 | $90.80 |
| Market cap | $1.09T | $34.26B |
| P/E ratio | 41.0 | 35.9 |
| ROE | 102.29% | 38.49% |
| Profit margin | 33.53% | 20.12% |
| Revenue growth | 47.70% | 13.10% |
| Dividend yield | 0.57% | — |
| Beta | 0.51 | 1.41 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs DXCM in plain English
- LLY is the bigger company — about 31.8× the market cap of DXCM.
- DXCM is cheaper on earnings (P/E 35.9 vs 41.0).
- LLY earns a higher return on equity (102% vs 38%).
- LLY is growing revenue faster (48% vs 13%).
- LLY pays a dividend (0.57%) while the other effectively doesn't.
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
DXCM return calculator
See what $1,000 in DexCom, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.